Puma Biotechnology Inc (PBYI) valuation
Puma Biotechnology P/E ratio history
Puma Biotechnology trades at 20.1 times its earnings over the last twelve months. At its last 3 fiscal year ends its P/E ranged from 4.9 (year to Dec 2024) to 9.8 (year to Dec 2025), with a median of 9.6.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $5.95 | $0.61 | 9.8 | 12.5 |
| Dec 31, 2024 | $3.05 | $0.62 | 4.9 | 9.2 |
| Dec 31, 2023 | $4.33 | $0.45 | 9.6 | — |
| Dec 31, 2022 | $4.23 | $0.00 | n/m | — |
| Dec 31, 2021 | $3.04 | -$0.72 | n/m | — |
| Dec 31, 2020 | $10.26 | -$1.52 | n/m | — |
| Dec 31, 2019 | $8.75 | -$1.95 | n/m | — |
| Dec 31, 2018 | $20.35 | -$2.99 | n/m | — |
| Dec 31, 2017 | $98.85 | -$7.84 | n/m | — |
| Dec 31, 2016 | $30.70 | -$8.29 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Puma Biotechnology valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Puma BiotechnologyPBYI | $531M | 20.1 | — | 2.3 |
| Nrc HealthNRC | $537M | 99.3 | 23.0 | 3.8 |
| Bright Minds BiosciencesDRUG | $539M | — | — | — |
| Tactile Systems TechnologyTCMD | $520M | 21.5 | 17.6 | 1.5 |
| Sbc Medical GroupSBC | $543M | 11.0 | 10.6 | 3.1 |
| Aclaris TherapeuticsACRS | $554M | — | — | 67.4 |
| ArvinasARVN | $507M | 32.8 | — | 1.6 |
| Sight SciencesSGHT | $507M | — | — | 6.1 |
| Mimedx GroupMDXG | $566M | — | 70.4 | 1.9 |
| Peer median | 27.1 | 20.3 | 3.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PBYI financials · PBYI returns
No forecast, no recommendation. This page describes Puma Biotechnology Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.